Phase I and II trials are currently assessing the potential of metformin in combination with anti-PD-1 and anti-PD-L1 therapies for various cancers, including melanoma (NCT04114136), NSCLC (NCT03048500), and colorectal cancer (NCT03800602) [129,130]. The gene discussed is PDCD1; the disease is melanoma.